4.6 Article

The in vitro effect of nebulised hypertonic saline on human bronchial epithelium

Journal

EUROPEAN RESPIRATORY JOURNAL
Volume 51, Issue 5, Pages -

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/13993003.02652-2017

Keywords

-

Funding

  1. Cystic Fibrosis Foundation [GORALS12LO, BUTTON07XX0]
  2. National Institutes of Health [1R01HL125280-01A1, P30DK065988-11]

Ask authors/readers for more resources

Inhaled hypertonic saline (HS) is an effective therapy for muco-obstructive lung diseases. However, the mechanism of action and principles pertinent to HS administration remain unclear. An in vitro system aerosolised HS to epithelial cells at rates comparable to in vivo conditions. Airway surface liquid (ASL) volume and cell height responses were measured by confocal microscopy under normal and hyperconcentrated mucus states. Aerosolised HS produced a rapid increase in ASL height and decrease in cell height. Added ASL volume was quickly reabsorbed following termination of nebulisation, although cell height did not recover within the same time frame. ASL volume responses to repeated HS administrations were blunted, but could be restored by a hypotonic saline bolus interposed between HS administrations. HS-induced ASL hydration was prolonged with hyperconcentrated mucus on the airway surface, with more modest reductions in cell volume. Aerosolised HS produced osmotically induced increases in ASL height that were limited by active sodium absorption and cell volume-induced reductions in cell water permeability. Mucus on airway surfaces prolonged the effect of HS via mucus-dependent osmotic forces, suggesting that the duration of action of HS is increased in patients with hyperconcentrated mucus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Respiratory System

The specialist as primary care provider in CF

Kelsey B. Haywood, Jennifer L. Goralski

JOURNAL OF CYSTIC FIBROSIS (2020)

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of single breath hyperpolarized129Xe MRI with dynamic19F MRI in cystic fibrosis lung disease

Andrew McCallister, Sang Hun Chung, Michael Antonacci, Margret Z. Powell, Agathe S. Ceppe, Scott H. Donaldson, Yueh Z. Lee, Rosa Tamara Branca, Jennifer L. Goralski

Summary: In CF subjects, ventilation abnormalities can be identified by both (19)F and (HPXe)-Xe-129 imaging, but these abnormalities are not entirely congruent. (19)F and (HPXe)-Xe-129 imaging provide complementary information that allows for differentiation of normally ventilated, slowly ventilated, and non-ventilated regions in the lungs.

MAGNETIC RESONANCE IN MEDICINE (2021)

Review Pediatrics

Novel imaging techniques for cystic fibrosis lung disease

Jennifer L. Goralski, Neil J. Stewart, Jason C. Woods

Summary: This review discusses the latest developments in lung imaging modalities for CF patients, ranging from commonly used chest radiography and CT scans to emerging techniques like structural/functional proton and hyperpolarized gas MRI. These imaging tools offer new possibilities for early disease detection and monitoring treatment efficacy.

PEDIATRIC PULMONOLOGY (2021)

Article Medicine, General & Internal

Dynamic Perfluorinated Gas MRI Shows Improved Lung Ventilation in People with Cystic Fibrosis after Elexacaftor/Tezacaftor/Ivacaftor: An Observational Study

Jennifer L. Goralski, Sang Hun Chung, Agathe S. Ceppe, Margret Z. Powell, Muthu Sakthivel, Brian D. Handly, Yueh Z. Lee, Scott H. Donaldson

Summary: The availability of highly effective CFTR modulators is revolutionizing the treatment of cystic fibrosis, and MRI-based imaging modalities are emerging as highly sensitive endpoints in monitoring the effectiveness of the treatment. This observational study demonstrates the ability of F-19 MRI and H-1 UTE MRI to detect improvements in lung structure and function after E/T/I treatment, further supporting their potential as outcome measures for cystic fibrosis research and drug development.

JOURNAL OF CLINICAL MEDICINE (2022)

Meeting Abstract Pediatrics

ELEXACAFTOR-IVACAFTOR-TEZACAFTOR IMPROVES CHRONIC RHINOSINUSITIS SYMPTOMS IN CYSTIC FIBROSIS

A. M. Stapleton, A. J. Kimple, J. L. Goralski, M. Nouraie, A. Shaffer, J. M. Pilewski, B. A. Senior, S. Lee, A. Zemke

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

IMPACT OF ELEXACAFTOR/TEZACAFTOR/yIVACAFTOR TRIPLE COMBINATION THERAPY ON HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH CYSTIC FIBROSIS HOMOZYGOUS FOR F508DEL: RESULTS FROM A PHASE 3 CLINICAL STUDY

C. J. Majoor, K. Van Brunt, C. Daines, I Durieu, I Fajac, J. L. Goralski, H. Heijerman, C. Knoop, J. Booth, S. M. Moskowitz, J. Savage, C. Wang, A. L. Quittner

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

REGIONAL ANALYSIS OF LUNG STRUCTURE, VENTILATION AND MUCOCILIARY CLEARANCE BY MRI AND SCINTIGRAPHY BEFORE AND AFTER ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

M. Mihailescu, A. Ceppe, S. Chung, J. L. Goralski, K. Zeman, B. Handly, M. Sakthivel, M. R. Markovetz, W. D. Bennett, Y. Lee, S. H. Donaldson

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

A NATURALLY-OCCURRING PHENYLALANINE DELETION IN TRANSMEMBRANE SEGMENT 5 IS ASSOCIATED WITH DIAGNOSTIC ELEVATION IN SWEAT CHLORIDE CONCENTRATION BUT ONLY MINIMAL LOSS OF CFTR CHLORIDE TRANSPORT FUNCTION

K. S. Raraigh, K. C. Paul, J. L. Goralski, E. N. Worthington, A. Faino, S. Sciortino, Y. Wang, M. A. Aksit, H. Ling, D. L. Osorio, F. M. Onchiri, S. Patel, C. Merlo, K. Montemayor, R. Gibson, N. E. West, D. N. Sheppard, N. Sharma, G. R. Cutting

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

A QUANTIFIED LIFE: A LONGITUDINAL QUALITATIVE DESCRIPTIVE ANALYSIS OF BLOGGERS WITH CYSTIC FIBROSIS

T. Girdwood, C. Jones, J. L. Goralski, A. Beeber

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

19F/1H UTE MRI DETECTS VENTILATION IMPROVEMENTS AFTER HIGHLY EFFECTIVE MODULATOR THERAPY

J. L. Goralski, S. Chung, M. Powell, A. Ceppe, M. Sakthivel, Y. Lee, S. H. Donaldson

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

OLFACTION AND BASLINE SINONASAL CHARACTERISTIC IN A CYSTIC FIBROSIS COHORT

A. J. Kimple, A. M. Stapleton, J. L. Goralski, M. Nouraie, A. Shaffer, J. M. Pilewski, B. A. Senior, A. Zemke, S. E. Lee

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

IMPLEMENTING A COLLABORATIVE CARE MODEL FOR MENTAL HEALTH CARE AT UNC

M. L. Buchanan, L. Rupcich, K. Wendel, J. L. Goralski, S. H. Donaldson, N. Sowa

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Pediatrics

IMPACT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR TRIPLE COMBINATION THERAPY ON HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH CYSTIC FIBROSIS HETEROZYGOUS FOR F508DEL AND A MINIMAL FUNCTION MUTATION: RESULTS FROM A PHASE 3 CLINICAL STUDY

I Fajac, K. Van Brunt, C. Daines, I Durieu, J. L. Goralski, H. Heijerman, C. Knoop, C. J. Majoor, J. Booth, S. M. Moskowitz, J. Savage, C. Wang, A. L. Quittner

PEDIATRIC PULMONOLOGY (2020)

Meeting Abstract Critical Care Medicine

A Unique Phenotype of a Rare Cystic Fibrosis Transmembrane Regulator Gene Mutation: C.935_937deltct (p.Phe312del)

E. Worthington, J. L. Goralski

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

Article Medicine, Research & Experimental

Dynamic perfluorinated gas MRI reveals abnormal ventilation despite normal FEV1 in cystic fibrosis

Jennifer L. Goralski, Sang Hun Chung, Tyler M. Glass, Agathe S. Ceppe, Esther O. Akinnagbe-Zusterzeel, Aaron T. Trimble, Richard C. Boucher, Brian J. Soher, H. Cecil Charles, Scott H. Donaldson, Yueh Z. Lee

JCI INSIGHT (2020)

No Data Available